Non–Small Cell Lung Cancer Coverage from Every Angle

Heather A. Wakelee, MD, on Clinical Implications of Treating NSCLC With Atezolizumab

Posted: Monday, May 24, 2021

Heather A. Wakelee, MD, of Stanford University Medical Center, discusses key phase III evidence from the IMpower010 trial on the efficacy of atezolizumab for patients with non–small cell lung cancer, those with PD-L1 expression who may benefit most from this agent, and potential toxicities.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.